However, these small molecular STING agonists face toxicity issues, and they are difficult to accumulate in the tumor microenvironment (TME), which limit the clinical translation of them.[7] Overall, targeted immunotherapy using STING agonists remains a big challenge of poor stability, low delivery efficiency, and potential toxicity. This evidence concerns the gene STING1 and neoplasm.